Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + Gefitinib in EGFR-mutant NSCLC (ACTIVE)
NCT02824458Phase 3Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2016
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02824458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02824458.